52 62. (Amended) The method of claim 57, wherein said polypeptide is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

53 89. (Amended) The method of claim 88, wherein said polypeptide is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

92. (Amended) The method of claim 82, wherein said polypeptide further comprises Met at
54 the N-terminus.

93. (Amended) The method of claim 82, wherein said polypeptide is unglycosylated.

55 95. (Amended) The method of claim 82, wherein the polypeptide consists of (a) a sufficient number of amino acids 32-64 of Figure 7 that said polypeptide has epithelial cell specificity, and (b) amino acids 65-194 of Figure 7.

56 150. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide prepared by expressing a DNA encoding a polypeptide comprising amino acids 32 - 194 of Figure 7.

154. (Amended) The method of claim 150, wherein said DNA is expressed in a bacterial cell, a fungal cell, a mammalian cell or an insect cell.

57 155. (Amended ) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32 to 194 of Figure 7 or a segment of said polypeptide, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK cells.

58 163. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that

remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

165. (Amended) The method of claim 163 wherein said polypeptide and said segment of said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.

166. (Amended) The method of claim 163, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity on epithelial cells.

167. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

169. (Amended) The method of claim 167, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK keratinocyte cells.

170. (Amended) The method of claim 167, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.

171. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78 and is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

173. (Amended) The method of claim 171, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK keratinocyte cells.

174. (Amended) The method of claim 171, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.

177. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide is prepared by expressing a DNA encoding a polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

J12

178. (Amended) The method of claim 177, wherein the DNA is expressed in a bacterial cell, a fungal cell, a mammalian cell or an insect cell.

180. (Amended) The method of claim 177, wherein said polypeptide and said segment of said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.

J13

181. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32 to 194 of Figure 7 or a segment of said polypeptide, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.

190. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78, and wherein said polypeptide is unglycosylated.

J14

191. (Amended) The method of one of claims 150-151, 153-174, 177-189, wherein said polypeptide is unglycosylated.

192. (Amended) The method of one of claims 150-151, 153-174, 177-189, wherein said polypeptide is glycosylated.